▶ 調査レポート

世界の胃抑制性ポリペプチド受容体市場 2021:企業別、地域別、種類・用途別

• 英文タイトル:Global Gastric Inhibitory Polypeptide Receptor Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

GlobalInfoResearchが調査・発行した産業分析レポートです。世界の胃抑制性ポリペプチド受容体市場 2021:企業別、地域別、種類・用途別 / Global Gastric Inhibitory Polypeptide Receptor Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 / GIR-107A14568資料のイメージです。• レポートコード:GIR-107A14568
• 出版社/出版日:GlobalInfoResearch / 2021年7月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、90ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料では、胃抑制性ポリペプチド受容体のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。胃抑制性ポリペプチド受容体の種類別市場規模(HM-15211、LBT-6030、LY-3298176、NNC-92041706、その他)、用途別市場規模(代謝障害、2型糖尿病、肥満、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・胃抑制性ポリペプチド受容体の市場概要
・企業情報(企業概要、製品概要、販売量、価格、売上):Alchemia Limited、AstraZeneca Plc、Carmot Therapeutics, Inc.、Diabetica Limited、Longevity Biotech, Inc、Novo Nordisk A/S、Sanofi、Zealand Pharma A/S
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:HM-15211、LBT-6030、LY-3298176、NNC-92041706、その他
・用途別分析2016年-2026年:代謝障害、2型糖尿病、肥満、その他
・胃抑制性ポリペプチド受容体の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・胃抑制性ポリペプチド受容体のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・胃抑制性ポリペプチド受容体のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・胃抑制性ポリペプチド受容体の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・胃抑制性ポリペプチド受容体の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Gastric Inhibitory Polypeptide Receptor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Gastric Inhibitory Polypeptide Receptor size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Gastric Inhibitory Polypeptide Receptor market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Gastric Inhibitory Polypeptide Receptor market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
HM-15211
LBT-6030
LY-3298176
NNC-92041706
Others

Market segment by Application can be divided into
Metabolic Disorder
Type 2 Diabetes
Obesity
Others

The key market players for global Gastric Inhibitory Polypeptide Receptor market are listed below:
Alchemia Limited
AstraZeneca Plc
Carmot Therapeutics, Inc.
Diabetica Limited
Longevity Biotech, Inc
Novo Nordisk A/S
Sanofi
Zealand Pharma A/S

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Gastric Inhibitory Polypeptide Receptor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Gastric Inhibitory Polypeptide Receptor, with price, sales, revenue and global market share of Gastric Inhibitory Polypeptide Receptor from 2019 to 2021.
Chapter 3, the Gastric Inhibitory Polypeptide Receptor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Gastric Inhibitory Polypeptide Receptor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Gastric Inhibitory Polypeptide Receptor market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Gastric Inhibitory Polypeptide Receptor sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

1 Market Overview
1.1 Gastric Inhibitory Polypeptide Receptor Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Gastric Inhibitory Polypeptide Receptor Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 HM-15211
1.2.3 LBT-6030
1.2.4 LY-3298176
1.2.5 NNC-92041706
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Gastric Inhibitory Polypeptide Receptor Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Metabolic Disorder
1.3.3 Type 2 Diabetes
1.3.4 Obesity
1.3.5 Others
1.4 Global Gastric Inhibitory Polypeptide Receptor Market Size & Forecast
1.4.1 Global Gastric Inhibitory Polypeptide Receptor Sales in Value (2016-2026))
1.4.2 Global Gastric Inhibitory Polypeptide Receptor Sales in Volume (2016-2026)
1.4.3 Global Gastric Inhibitory Polypeptide Receptor Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Gastric Inhibitory Polypeptide Receptor Production Capacity Analysis
1.5.1 Global Gastric Inhibitory Polypeptide Receptor Total Production Capacity (2016-2026)
1.5.2 Global Gastric Inhibitory Polypeptide Receptor Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Gastric Inhibitory Polypeptide Receptor Market Drivers
1.6.2 Gastric Inhibitory Polypeptide Receptor Market Restraints
1.6.3 Gastric Inhibitory Polypeptide Receptor Trends Analysis
2 Manufacturers Profiles
2.1 Alchemia Limited
2.1.1 Alchemia Limited Details
2.1.2 Alchemia Limited Major Business
2.1.3 Alchemia Limited Gastric Inhibitory Polypeptide Receptor Product and Services
2.1.4 Alchemia Limited Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 AstraZeneca Plc
2.2.1 AstraZeneca Plc Details
2.2.2 AstraZeneca Plc Major Business
2.2.3 AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Product and Services
2.2.4 AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Carmot Therapeutics, Inc.
2.3.1 Carmot Therapeutics, Inc. Details
2.3.2 Carmot Therapeutics, Inc. Major Business
2.3.3 Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Product and Services
2.3.4 Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Diabetica Limited
2.4.1 Diabetica Limited Details
2.4.2 Diabetica Limited Major Business
2.4.3 Diabetica Limited Gastric Inhibitory Polypeptide Receptor Product and Services
2.4.4 Diabetica Limited Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Longevity Biotech, Inc
2.5.1 Longevity Biotech, Inc Details
2.5.2 Longevity Biotech, Inc Major Business
2.5.3 Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Product and Services
2.5.4 Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Novo Nordisk A/S
2.6.1 Novo Nordisk A/S Details
2.6.2 Novo Nordisk A/S Major Business
2.6.3 Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Product and Services
2.6.4 Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business
2.7.3 Sanofi Gastric Inhibitory Polypeptide Receptor Product and Services
2.7.4 Sanofi Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Zealand Pharma A/S
2.8.1 Zealand Pharma A/S Details
2.8.2 Zealand Pharma A/S Major Business
2.8.3 Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Product and Services
2.8.4 Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Gastric Inhibitory Polypeptide Receptor Sales by Manufacturer
3.1 Global Gastric Inhibitory Polypeptide Receptor Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Gastric Inhibitory Polypeptide Receptor
3.4 Market Concentration Rate
3.4.1 Top 3 Gastric Inhibitory Polypeptide Receptor Manufacturer Market Share
3.4.2 Top 6 Gastric Inhibitory Polypeptide Receptor Manufacturer Market Share
3.5 Global Gastric Inhibitory Polypeptide Receptor Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Gastric Inhibitory Polypeptide Receptor Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Gastric Inhibitory Polypeptide Receptor Market Size by Region
4.1.1 Global Gastric Inhibitory Polypeptide Receptor Sales in Volume by Region (2016-2026)
4.1.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Region (2016-2026)
4.2 North America Gastric Inhibitory Polypeptide Receptor Revenue (2016-2026)
4.3 Europe Gastric Inhibitory Polypeptide Receptor Revenue (2016-2026)
4.4 Asia-Pacific Gastric Inhibitory Polypeptide Receptor Revenue (2016-2026)
4.5 South America Gastric Inhibitory Polypeptide Receptor Revenue (2016-2026)
4.6 Middle East and Africa Gastric Inhibitory Polypeptide Receptor Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Gastric Inhibitory Polypeptide Receptor Sales in Volume by Type (2016-2026)
5.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Type (2016-2026)
5.3 Global Gastric Inhibitory Polypeptide Receptor Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Gastric Inhibitory Polypeptide Receptor Sales in Volume by Application (2016-2026)
6.2 Global Gastric Inhibitory Polypeptide Receptor Revenue by Application (2016-2026)
6.3 Global Gastric Inhibitory Polypeptide Receptor Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Gastric Inhibitory Polypeptide Receptor Sales by Type (2016-2026)
7.2 North America Gastric Inhibitory Polypeptide Receptor Sales by Application (2016-2026)
7.3 North America Gastric Inhibitory Polypeptide Receptor Market Size by Country
7.3.1 North America Gastric Inhibitory Polypeptide Receptor Sales in Volume by Country (2016-2026)
7.3.2 North America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Gastric Inhibitory Polypeptide Receptor Sales by Type (2016-2026)
8.2 Europe Gastric Inhibitory Polypeptide Receptor Sales by Application (2016-2026)
8.3 Europe Gastric Inhibitory Polypeptide Receptor Market Size by Country
8.3.1 Europe Gastric Inhibitory Polypeptide Receptor Sales in Volume by Country (2016-2026)
8.3.2 Europe Gastric Inhibitory Polypeptide Receptor Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales by Type (2016-2026)
9.2 Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales by Application (2016-2026)
9.3 Asia-Pacific Gastric Inhibitory Polypeptide Receptor Market Size by Region
9.3.1 Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Gastric Inhibitory Polypeptide Receptor Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Gastric Inhibitory Polypeptide Receptor Sales by Type (2016-2026)
10.2 South America Gastric Inhibitory Polypeptide Receptor Sales by Application (2016-2026)
10.3 South America Gastric Inhibitory Polypeptide Receptor Market Size by Country
10.3.1 South America Gastric Inhibitory Polypeptide Receptor Sales in Volume by Country (2016-2026)
10.3.2 South America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Type (2016-2026)
11.2 Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Application (2016-2026)
11.3 Middle East & Africa Gastric Inhibitory Polypeptide Receptor Market Size by Country
11.3.1 Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Gastric Inhibitory Polypeptide Receptor Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Gastric Inhibitory Polypeptide Receptor Typical Distributors
12.3 Gastric Inhibitory Polypeptide Receptor Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Gastric Inhibitory Polypeptide Receptor Revenue by Type, (USD Million), 2021-2026
Table 2. Global Gastric Inhibitory Polypeptide Receptor Revenue by Application, (USD Million), 2021-2026
Table 3. Alchemia Limited Basic Information, Manufacturing Base and Competitors
Table 4. Alchemia Limited Major Business
Table 5. Alchemia Limited Gastric Inhibitory Polypeptide Receptor Product and Services
Table 6. Alchemia Limited Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. AstraZeneca Plc Basic Information, Manufacturing Base and Competitors
Table 8. AstraZeneca Plc Major Business
Table 9. AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Product and Services
Table 10. AstraZeneca Plc Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Carmot Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 12. Carmot Therapeutics, Inc. Major Business
Table 13. Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Product and Services
Table 14. Carmot Therapeutics, Inc. Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Diabetica Limited Basic Information, Manufacturing Base and Competitors
Table 16. Diabetica Limited Major Business
Table 17. Diabetica Limited Gastric Inhibitory Polypeptide Receptor Product and Services
Table 18. Diabetica Limited Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Longevity Biotech, Inc Basic Information, Manufacturing Base and Competitors
Table 20. Longevity Biotech, Inc Major Business
Table 21. Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Product and Services
Table 22. Longevity Biotech, Inc Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
Table 24. Novo Nordisk A/S Major Business
Table 25. Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Product and Services
Table 26. Novo Nordisk A/S Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Sanofi Basic Information, Manufacturing Base and Competitors
Table 28. Sanofi Major Business
Table 29. Sanofi Gastric Inhibitory Polypeptide Receptor Product and Services
Table 30. Sanofi Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Zealand Pharma A/S Basic Information, Manufacturing Base and Competitors
Table 32. Zealand Pharma A/S Major Business
Table 33. Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Product and Services
Table 34. Zealand Pharma A/S Gastric Inhibitory Polypeptide Receptor Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Global Gastric Inhibitory Polypeptide Receptor Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 36. Global Gastric Inhibitory Polypeptide Receptor Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 37. Market Position of Manufacturers in Gastric Inhibitory Polypeptide Receptor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 38. Global Gastric Inhibitory Polypeptide Receptor Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 39. Head Office and Gastric Inhibitory Polypeptide Receptor Production Site of Key Manufacturer
Table 40. Gastric Inhibitory Polypeptide Receptor New Entrant and Capacity Expansion Plans
Table 41. Gastric Inhibitory Polypeptide Receptor Mergers & Acquisitions in the Past Five Years
Table 42. Global Gastric Inhibitory Polypeptide Receptor Sales by Region (2016-2021e) & (K Pcs)
Table 43. Global Gastric Inhibitory Polypeptide Receptor Sales by Region (2021-2026) & (K Pcs)
Table 44. Global Gastric Inhibitory Polypeptide Receptor Revenue by Region (2016-2021e) & (USD Million)
Table 45. Global Gastric Inhibitory Polypeptide Receptor Revenue by Region (2021-2026) & (USD Million)
Table 46. Global Gastric Inhibitory Polypeptide Receptor Sales by Type (2016-2021e) & (K Pcs)
Table 47. Global Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2026) & (K Pcs)
Table 48. Global Gastric Inhibitory Polypeptide Receptor Revenue by Type (2016-2021e) & (USD Million)
Table 49. Global Gastric Inhibitory Polypeptide Receptor Revenue by Type (2021-2026) & (USD Million)
Table 50. Global Gastric Inhibitory Polypeptide Receptor Price by Type (2016-2021e) & (USD/Pcs)
Table 51. Global Gastric Inhibitory Polypeptide Receptor Price by Type (2021-2026) & (USD/Pcs)
Table 52. Global Gastric Inhibitory Polypeptide Receptor Sales by Application (2016-2021e) & (K Pcs)
Table 53. Global Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2026) & (K Pcs)
Table 54. Global Gastric Inhibitory Polypeptide Receptor Revenue by Application (2016-2021e) & (USD Million)
Table 55. Global Gastric Inhibitory Polypeptide Receptor Revenue by Application (2021-2026) & (USD Million)
Table 56. Global Gastric Inhibitory Polypeptide Receptor Price by Application (2016-2021e) & (USD/Pcs)
Table 57. Global Gastric Inhibitory Polypeptide Receptor Price by Application (2021-2026) & (USD/Pcs)
Table 58. North America Gastric Inhibitory Polypeptide Receptor Sales by Country (2016-2021e) & (K Pcs)
Table 59. North America Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2026) & (K Pcs)
Table 60. North America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2016-2021e) & (USD Million)
Table 61. North America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2021-2026) & (USD Million)
Table 62. North America Gastric Inhibitory Polypeptide Receptor Sales by Type (2016-2021e) & (K Pcs)
Table 63. North America Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2026) & (K Pcs)
Table 64. North America Gastric Inhibitory Polypeptide Receptor Sales by Application (2016-2021e) & (K Pcs)
Table 65. North America Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2026) & (K Pcs)
Table 66. Europe Gastric Inhibitory Polypeptide Receptor Sales by Country (2016-2021e) & (K Pcs)
Table 67. Europe Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2026) & (K Pcs)
Table 68. Europe Gastric Inhibitory Polypeptide Receptor Revenue by Country (2016-2021e) & (USD Million)
Table 69. Europe Gastric Inhibitory Polypeptide Receptor Revenue by Country (2021-2026) & (USD Million)
Table 70. Europe Gastric Inhibitory Polypeptide Receptor Sales by Type (2016-2021e) & (K Pcs)
Table 71. Europe Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2026) & (K Pcs)
Table 72. Europe Gastric Inhibitory Polypeptide Receptor Sales by Application (2016-2021e) & (K Pcs)
Table 73. Europe Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2026) & (K Pcs)
Table 74. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales by Region (2016-2021e) & (K Pcs)
Table 75. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales by Region (2021-2026) & (K Pcs)
Table 76. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Revenue by Region (2016-2021e) & (USD Million)
Table 77. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Revenue by Region (2021-2026) & (USD Million)
Table 78. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales by Type (2016-2021e) & (K Pcs)
Table 79. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2026) & (K Pcs)
Table 80. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales by Application (2016-2021e) & (K Pcs)
Table 81. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2026) & (K Pcs)
Table 82. South America Gastric Inhibitory Polypeptide Receptor Sales by Country (2016-2021e) & (K Pcs)
Table 83. South America Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2026) & (K Pcs)
Table 84. South America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2016-2021e) & (USD Million)
Table 85. South America Gastric Inhibitory Polypeptide Receptor Revenue by Country (2021-2026) & (USD Million)
Table 86. South America Gastric Inhibitory Polypeptide Receptor Sales by Type (2016-2021e) & (K Pcs)
Table 87. South America Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2026) & (K Pcs)
Table 88. South America Gastric Inhibitory Polypeptide Receptor Sales by Application (2016-2021e) & (K Pcs)
Table 89. South America Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2026) & (K Pcs)
Table 90. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Country (2016-2021e) & (K Pcs)
Table 91. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Country (2021-2026) & (K Pcs)
Table 92. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Revenue by Country (2016-2021e) & (USD Million)
Table 93. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Revenue by Country (2021-2026) & (USD Million)
Table 94. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Type (2016-2021e) & (K Pcs)
Table 95. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Type (2021-2026) & (K Pcs)
Table 96. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Application (2016-2021e) & (K Pcs)
Table 97. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales by Application (2021-2026) & (K Pcs)
Table 98. Direct Channel Pros & Cons
Table 99. Indirect Channel Pros & Cons
Table 100. Gastric Inhibitory Polypeptide Receptor Typical Distributors
Table 101. Gastric Inhibitory Polypeptide Receptor Typical Customers
List of Figures
Figure 1. Gastric Inhibitory Polypeptide Receptor Picture
Figure 2. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type in 2020
Figure 3. HM-15211
Figure 4. LBT-6030
Figure 5. LY-3298176
Figure 6. NNC-92041706
Figure 7. Others
Figure 8. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application in 2020
Figure 9. Metabolic Disorder
Figure 10. Type 2 Diabetes
Figure 11. Obesity
Figure 12. Others
Figure 13. Global Gastric Inhibitory Polypeptide Receptor Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 14. Global Gastric Inhibitory Polypeptide Receptor Market Size and Forecast (2016-2026) & (USD Million)
Figure 15. Global Gastric Inhibitory Polypeptide Receptor Sales (2016-2026) & (K Pcs)
Figure 16. Global Gastric Inhibitory Polypeptide Receptor Price by Type (2016-2026) & (USD/Pcs)
Figure 17. Global Gastric Inhibitory Polypeptide Receptor Production Capacity (2016-2026) & (K Pcs)
Figure 18. Global Gastric Inhibitory Polypeptide Receptor Production Capacity by Geographic Region: 2020 VS 2021
Figure 19. Gastric Inhibitory Polypeptide Receptor Market Drivers
Figure 20. Gastric Inhibitory Polypeptide Receptor Market Restraints
Figure 21. Gastric Inhibitory Polypeptide Receptor Market Trends
Figure 22. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Manufacturer in 2020
Figure 23. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Manufacturer in 2020
Figure 24. Gastric Inhibitory Polypeptide Receptor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 25. Top 3 Gastric Inhibitory Polypeptide Receptor Manufacturer (Revenue) Market Share in 2020
Figure 26. Top 6 Gastric Inhibitory Polypeptide Receptor Manufacturer (Revenue) Market Share in 2020
Figure 27. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2016-2026)
Figure 28. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Region (2016-2026)
Figure 29. North America Gastric Inhibitory Polypeptide Receptor Revenue (2016-2026) & (USD Million)
Figure 30. Europe Gastric Inhibitory Polypeptide Receptor Revenue (2016-2026) & (USD Million)
Figure 31. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Revenue (2016-2026) & (USD Million)
Figure 32. South America Gastric Inhibitory Polypeptide Receptor Revenue (2016-2026) & (USD Million)
Figure 33. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Revenue (2016-2026) & (USD Million)
Figure 34. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2016-2026)
Figure 35. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Type (2016-2026)
Figure 36. Global Gastric Inhibitory Polypeptide Receptor Price by Type (2016-2026) & (USD/Pcs)
Figure 37. Global Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2016-2026)
Figure 38. Global Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Application (2016-2026)
Figure 39. Global Gastric Inhibitory Polypeptide Receptor Price by Application (2016-2026) & (USD/Pcs)
Figure 40. North America Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2016-2026)
Figure 41. North America Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2016-2026)
Figure 42. North America Gastric Inhibitory Polypeptide Receptor Sales Market Share by Country (2016-2026)
Figure 43. North America Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Country (2016-2026)
Figure 44. United States Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2016-2026)
Figure 48. Europe Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2016-2026)
Figure 49. Europe Gastric Inhibitory Polypeptide Receptor Sales Market Share by Country (2016-2026)
Figure 50. Europe Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Country (2016-2026)
Figure 51. Germany Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Sales Market Share by Region (2016-2026)
Figure 59. Asia-Pacific Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Region (2016-2026)
Figure 60. China Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Korea Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2016-2026)
Figure 67. South America Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2016-2026)
Figure 68. South America Gastric Inhibitory Polypeptide Receptor Sales Market Share by Country (2016-2026)
Figure 69. South America Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales Market Share by Application (2016-2026)
Figure 74. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Sales Market Share by Country (2016-2026)
Figure 75. Middle East & Africa Gastric Inhibitory Polypeptide Receptor Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Egypt Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. South Africa Gastric Inhibitory Polypeptide Receptor Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source